AGL vs MRK
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
The Advanced Deterministic Scorecard reveals a weak financial health profile with a Piotroski F-Score of 4/9, indicating borderline stability, and a missing Altman Z-Score prevents a full distress risk assessment. Profitability metrics are deeply negative, including a -5.24% profit margin, -8.86% operating margin, and a disastrous -73.31% ROE, signaling severe capital inefficiency. Despite a low Price/Sales ratio of 0.07 and a current price of $0.99, the company is unprofitable with declining revenue and negative earnings momentum, while the market has priced in extreme pessimism, as seen in a 5Y return of -96.8%. Analysts unanimously recommend a 'hold' with a target price equal to the current price, suggesting no near-term upside expectation.
MRK shows neutral fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Mixed signals with both opportunities and risks present.
Compare Another Pair
Related Comparisons
AGL vs MRK: Head-to-Head Comparison
This page compares agilon health, inc. (AGL) and Merck & Co., Inc. (MRK) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.